Enhanced Efficacy of Immunization with a Foot-and-Mouth Disease Multi-Epitope Subunit Vaccine Using Mannan-Decorated Inulin Microparticles
10.1007/s13770-019-00228-5
- Author:
So-Yeon YOON
1
;
Sang-Kee KANG
;
Ho-Bin LEE
;
Seo-Ho OH
;
Whee-Soo KIM
;
Hui-Shan LI
;
Jin-Duck BOK
;
Chong-Su CHO
;
Yun-Jaie CHOI
Author Information
1. Department of Agricultural Biotechnology and Research Institute of Agriculture and Life Science, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea
- Publication Type:Original Article
- From:
Tissue Engineering and Regenerative Medicine
2020;17(1):33-44
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND:Despite the many advantages of recombinant subunit vaccines, they have critical weaknesses that include a low efficacy for promoting cellular and humoral immune responses against antigens because of their poor immunogenicity, and a rapidly cleared properties as a result of proteolytic enzymes in the body. To circumvent these problems, we developed mannan-decorated inulin acetate microparticles (M-IA MPs) that functioned as carriers and adjuvants for immunization with the recombinant foot-and-mouth disease multi-epitope subunit vaccine (M5BT).
METHODS:The M5BT-loaded M-IA MPs were obtained by a double-emulsion solvent-evaporation method. Their properties including morphology, size and release ability were determined by field emission scanning electron microscope, dynamic light-scattering spectrophotometer and spectrophotometer. To assess the immunization efficacy of the MPs, mice were immunized with MPs and their sera were analyzed by ELISA.
RESULTS:The M-IA MPs obtained by a double-emulsion solvent-evaporation method were spherical and approximately 2–3 µm, and M5BT was encapsulated in the M-IA MPs. The M5BT-loaded M-IA MPs showed higher antigen-specific IgG, IgG1, IgG2a and anti-FMDV antibodies than the M5BT-loaded IA MPs and the Freund’s adjuvant as a control.
CONCLUSION:The M-IA MPs showed a powerful and multifunctional polymeric system that combined two toll-like receptor agonists compared to the conventional adjuvant.
